Rowland Carmichael Advisors’s AbbVie ABBV Stock Holding History

Rowland Carmichael Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$411K	Buy	3,834 +88	+2%	+$8.46K	0.13%	170
2020 Q3	$328K	Buy	3,746 +30	+0.8%	+$2.82K	0.13%	181
2020 Q2	$365K	Buy	3,716 +31	+0.8%	+$2.73K	0.16%	162
2020 Q1	$281K	Buy	3,685 +213	+6%	+$18.1K	0.14%	180
2019 Q4	$307K	Hold	3,472	–	–	0.11%	218
2019 Q3	$263K	Buy	3,472 +431	+14%	+$29.5K	0.09%	241
2019 Q2	$221K	Hold	3,041	–	–	0.08%	248
2019 Q1	$245K	Hold	3,041	–	–	0.09%	221
2018 Q4	$280K	Hold	3,041	–	–	0.12%	181
2018 Q3	$288K	Hold	3,041	–	–	0.11%	200
2018 Q2	$282K	Sell	3,041 -47	-2%	-$4.59K	0.12%	202
2018 Q1	$292K	Hold	3,088	–	–	0.16%	176
2017 Q4	$299K	Sell	3,088 -128	-4%	-$12.1K	0.15%	178
2017 Q3	$286K	Buy	3,216 +128	+4%	+$9.74K	0.16%	172
2017 Q2	$224K	Sell	3,088 -100	-3%	-$6.72K	0.13%	200
2017 Q1	$208K	Sell	3,188 -500	-14%	-$31.4K	0.13%	207
2016 Q4	$231K	Sell	3,688 -14,069	-79%	-$859K	0.14%	205
2016 Q3	$1.12M	Buy	17,757 +924	+5%	+$59.8K	0.71%	34
2016 Q2	$1.04M	Buy	16,833 +1,213	+8%	+$73.9K	0.66%	40
2016 Q1	$892K	Buy	+15,620	New	+$871K	0.82%	33

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rowland Carmichael Advisors's ABBV Position: Q4 2020 in Review

Rowland Carmichael Advisors increased its AbbVie (ABBV) stake by 2.3% in Q4 2020, buying an estimated $8.46K and bringing the position to 3,834 shares worth $411K. The position accounts for 0.13% of the portfolio, ranked #170.

Rowland Carmichael Advisors first reported a position in ABBV in Q1 2016 and has held it in 20 quarters since. The position peaked at $1.12M in Q3 2016. 2,597 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

Rowland Carmichael Advisors held 3,834 shares of AbbVie worth $411K as of Q4 2020.
Rowland Carmichael Advisors bought 88 AbbVie shares in Q4 2020, an estimated $8.46K.
AbbVie made up 0.13% of Rowland Carmichael Advisors's portfolio in Q4 2020, its #170 holding.
Rowland Carmichael Advisors first reported a position in AbbVie in Q1 2016 and has held it in 20 quarters since.
Rowland Carmichael Advisors's AbbVie position peaked at $1.12M in Q3 2016.
2,597 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Rowland Carmichael Advisors's 13F filing for Q4 2020, filed 15 Jan 2021.